Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...

Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...

Jazz Pharmaceuticals (JAZZ) stock gains as lung cancer drug Zepzelca with Roche's (RHHBY) Tecentriq hits main goal in Phase 3 ...

When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...

Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...